Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
Information source: Nihon Pharmaceutical Co., Ltd
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bullous Pemphigoid
Intervention: NPB-01 (Drug); Placebo (Drug)
Phase: Phase 2
Sponsored by: Nihon Pharmaceutical Co., Ltd
Patients diagnosed with bullous pemphigoid were confirmed based on the investigators
national diagnostic criteria. Patients who meet all inclusion criteria and conflict the
exclusion criteria will receive NPB-01(intravenous immunoglobulin) 400mg/kg/day for five
consecutive days or Placebo(physiological saline). Subsequently, efficacy of NPB-01 for
therapy of bullous pemphigoid will evaluate using pemphigoid activity score involving skin
lesion area and Number of new blisters.
As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse
events by 57 days after the start of the study treatment.
Official title: NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ).
Study design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Skin lesion area (%), Number of new blisters/day, Pemphigoid Activity Score, Pemphigus Disease Area Index(PDAI), anti-BP180 and -BP230 antibody titers, Steroid dose, Time to escape from the protocol and its ratio
Minimum age: 20 Years.
Maximum age: N/A.
1. Patients with corticosteroids over 20mg/day(Prednisolone) at informed consent.
2. Patients with continued treatment for bullous pemphigoid without add or change the
treatment after informed consent.
3. Patients who pemphigoid activity score is score1 and more before study medication
4. Patients who symptom is not improve before study medication received.
5. Patients with twenty years old at informed consent.
6. Patients with hospitalization during five consecutive days of study medication.
1. Patients treated with plasmapheresis at 28 days before informed consent.
2. Patients treated with corticosteroids pulse therapy(methylprednisolone over 0. 5g/day)
at 14 days before informed consent.
3. Patients treated with intravenous immunoglobulin at 56 days before informed consent.
4. Patients who receive or adjust in increments immunosuppressants at 14 days before
5. Patients with malignancy or a history of this disease.
6. Patients with history of shock for NPB-01.
7. Patients with history of hypersensitivity for NPB-01.
8. Patients with IgA deficiency.
9. Patients with impaired liver function.
10. Patients with impaired renal function.
11. Patients with cerebro- or cardiovascular disorders.
12. Patients with high risk of thromboembolism.
13. Patients with hemolytic/hemorrhagic anemia.
14. Patients with decreased cardiac function.
15. Patients with decreased platelet.
Locations and Contacts
Osaka, Japan; Recruiting
Yasumasa Ogawa, Email: email@example.com
Starting date: December 2008
Last updated: June 3, 2009